Compass Therapeutics Inc (NASDAQ: CMPX) is 211.88% higher on its value in year-to-date trading and has touched a low of $0.87 and a high of $4.08 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CMPX stock was last observed hovering at around $3.13 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $3.15, the stock is 16.39% and 33.01% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.24 million and changing 0.64% at the moment leaves the stock 46.13% off its SMA200. CMPX registered 117.24% gain for a year compared to 6-month gain of 57.50%. The firm has a 50-day simple moving average (SMA 50) of $2.2944 and a 200-day simple moving average (SMA200) of $2.135625.
The stock witnessed a 32.91% loss in the last 1 month and extending the period to 3 months gives it a 85.29%, and is 10.53% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.20% over the week and 7.71% over the month.
Compass Therapeutics Inc (CMPX) has around 35 employees, a market worth around $435.59M and $0.85M in sales. Profit margin for the company is -6496.35%. Distance from 52-week low is 260.37% and -22.79% from its 52-week high. The company has generated returns on investments over the last 12 months (-47.38%).
The EPS is expected to shrink by -39.17% this year
138.0 institutions hold shares in Compass Therapeutics Inc (CMPX), with institutional investors hold 81.57% of the company’s shares. The shares outstanding are 138.28M, and float is at 87.95M with Short Float at 8.41%. Institutions hold 70.02% of the Float.
The top institutional shareholder in the company is ORBIMED ADVISORS LLC with over 22.36 million shares valued at $22.36 million. The investor’s holdings represent 16.2534 of the CMPX Shares outstanding. As of 2024-06-30, the second largest holder is ADAGE CAPITAL PARTNERS GP, L.L.C. with 11.13 million shares valued at $11.13 million to account for 8.0893 of the shares outstanding. The other top investors are BLACKSTONE INC. which holds 7.69 million shares representing 5.5902 and valued at over $7.69 million, while BLACKROCK INC. holds 4.8068 of the shares totaling 6.61 million with a market value of $6.61 million.
Compass Therapeutics Inc (CMPX) Insider Activity
The most recent transaction is an insider purchase by Schuetz Thomas J., the company’s CHIEF EXECUTIVE OFFICER. SEC filings show that Schuetz Thomas J. bought 10,000 shares of the company’s common stock on May 27 ’25 at a price of $2.11 per share for a total of $21100.0. Following the purchase, the insider now owns 6.48 million shares.
Compass Therapeutics Inc disclosed in a document filed with the SEC on Apr 09 ’25 that GORDON CARL L (Director) sold a total of 3,571,428 shares of the company’s common stock. The trade occurred on Apr 09 ’25 and was made at $1.59 per share for $5.68 million. Following the transaction, the insider now directly holds 0.0 shares of the CMPX stock.
Still, SEC filings show that on Apr 09 ’25, ORBIMED ADVISORS LLC (Director) disposed off 3,571,428 shares at an average price of $1.59 for $5.68 million. The insider now directly holds 0 shares of Compass Therapeutics Inc (CMPX).
